Errol de Souza
Chairman at CYCLERION THERAPEUTICS, INC.
Net worth: 31 M $ as of 2024-05-30
Profile
Dr. Errol B.
de Souza is an Independent Director at Alector, Inc., a Chairman at Cyclerion Therapeutics, Inc., an Independent Director at Royalty Pharma Plc and a President & Director at nLife Therapeutics SL.
He is on the Board of Directors at Alector, Inc., Royalty Pharma Plc, Kures, Inc. and nLife Therapeutics SL.
Dr. de Souza was previously employed as a President, Chief Executive Officer & Director by Neuropore Therapies, Inc., an Independent Director by Gyre Therapeutics, Inc., a President, Chief Executive Officer & Director by Biodel, Inc., a Non-Executive Director by Bionomics Ltd., an Independent Director by Targacept, Inc., a President, Chief Executive Officer & Director by Archemix Corp., a President, Chief Executive Officer & Director by Synaptic Pharmaceutical Corp., a Senior VP, Head-US Research & Development by Aventis Pharmaceuticals, Inc., a Senior VP, Head-US Research & Development by Hoechst Marion Roussel, Inc., a Director, Executive VP-Research & Development by Neurocrine Biosciences, Inc., a Head-CNS Diseases Research by DuPont Merck Pharmaceutical Co., a President & Chief Executive Officer by Albireo Pharma, Inc., and a Chairman-Technology Committee by Merial, Inc. He also served on the board at Palatin Technologies, Inc. and IDEXX Laboratories, Inc. He received his undergraduate degree from the University of Toronto and a doctorate degree from the University of Toronto.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
RPI US Partners 2019 LP
0.25% | 2020-06-15 | 539,150 ( 0.25% ) | 15 M $ | 2024-05-30 |
| 2024-04-11 | 500,140 ( 0.21% ) | 14 M $ | 2024-05-30 | |
| 2024-06-06 | 73,738 ( 0.02% ) | 2 M $ | 2024-05-30 | |
| 2024-04-16 | 50,000 ( 1.84% ) | 133 500 $ | 2024-05-30 | |
ALECTOR, INC.
-.--% | 2024-03-30 | 0 ( -.--% ) | - $ | 2024-05-30 |
Errol de Souza active positions
| Companies | Position | Start |
|---|---|---|
| ROYALTY PHARMA PLC | Director/Board Member | 2020-05-31 |
| CYCLERION THERAPEUTICS, INC. | Chairman | - |
| ALECTOR, INC. | Director/Board Member | 2024-03-18 |
Kures, Inc.
 Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | Director/Board Member | - |
nLife Therapeutics SL
 nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | President | - |
Former positions of Errol de Souza
| Companies | Position | End |
|---|---|---|
| BIONOMICS LIMITED | Chairman | 2023-06-30 |
| CATALYST BIOSCIENCES | Director/Board Member | 2022-12-25 |
Neuropore Therapies, Inc.
 Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Chief Executive Officer | 2019-11-30 |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Chief Executive Officer | 2016-01-25 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Errol de Souza
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| IDEXX LABORATORIES, INC. | Health Technology |
| PALATIN TECHNOLOGIES, INC. | Health Technology |
| BIONOMICS LIMITED | Health Technology |
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| ROYALTY PHARMA PLC | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| ALECTOR, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
| Hoechst Marion Roussel, Inc. | |
Merial, Inc.
 Merial, Inc. Pharmaceuticals: MajorHealth Technology Merial, Inc. develops pharmaceutical products and vaccines for pets and wildlife. It provides healthcare products and food for dogs, cats, cattle, horse, and poultry producers. The company was founded in August 1997 and is headquartered in Duluth, GA. | Health Technology |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Health Technology |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
nLife Therapeutics SL
nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Neuropore Therapies, Inc.
Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Health Services |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | Health Technology |
- Stock Market
- Insiders
- Errol de Souza
